Cargando…
A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma
BACKGROUND: The primary objective of this study was to determine the maximum tolerated dose (MTD) of escalating doses of radiotherapy (RT) concomitantly with a fixed dose of gemcitabine (300 mg/m(2)/week) within the same overall treatment time. METHODS: Thirteen patients were included. Gemcitabine 3...
Autores principales: | Budiharto, Tom, Haustermans, Karin, Van Cutsem, Eric, Van Steenbergen, Werner, Topal, Baki, Aerts, Raymond, Ectors, Nadine, Bielen, Didier, Vanbeckevoort, Dirk, Goethals, Laurence, Verslype, Chris |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2557003/ https://www.ncbi.nlm.nih.gov/pubmed/18808686 http://dx.doi.org/10.1186/1748-717X-3-30 |
Ejemplares similares
-
Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer
por: Bulle, Ashenafi, et al.
Publicado: (2020) -
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
por: Van Cutsem, E, et al.
Publicado: (2014) -
Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
por: Kim, R D, et al.
Publicado: (2018) -
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer
por: Chen, Justin A., et al.
Publicado: (2022) -
Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine
por: Van den broeck, Anke, et al.
Publicado: (2012)